BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26251521)

  • 1. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.
    Röcken C; Behrens HM; Böger C; Krüger S
    J Clin Pathol; 2016 Jan; 69(1):70-5. PubMed ID: 26251521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma.
    Chang KK; Cho SJ; Yoon C; Lee JH; Park DJ; Yoon SS
    Ann Surg Oncol; 2016 Dec; 23(13):4238-4246. PubMed ID: 27364501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.
    Schoop I; Maleki SS; Behrens HM; Krüger S; Haag J; Röcken C
    Hum Pathol; 2020 Nov; 105():53-66. PubMed ID: 32971129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation.
    Rokutan H; Arai Y; Kunita A; Yamasaki S; Nakamura H; Hama N; Nakayama A; Hosoda F; Totoki Y; Fujishiro M; Seto Y; Shibata T; Ushiku T
    Am J Surg Pathol; 2024 Jun; 48(6):652-661. PubMed ID: 38584451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
    Böger C; Krüger S; Behrens HM; Bock S; Haag J; Kalthoff H; Röcken C
    Ann Oncol; 2017 May; 28(5):1005-1014. PubMed ID: 28453696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
    Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
    Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
    Ushiku T; Ishikawa S; Kakiuchi M; Tanaka A; Katoh H; Aburatani H; Lauwers GY; Fukayama M
    Gastric Cancer; 2016 Apr; 19(2):403-411. PubMed ID: 25823974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes.
    Kwon CH; Kim YK; Lee S; Kim A; Park HJ; Choi Y; Won YJ; Park DY; Lauwers GY
    Histopathology; 2018 Mar; 72(4):556-568. PubMed ID: 28873240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
    Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.
    Huang KH; Lan YT; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Chiou SH; Yang MH; Shyr YM; Fang WL
    World J Surg; 2015 Sep; 39(9):2289-99. PubMed ID: 26013205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are PIK3CA Mutation and Amplification Associated with Clinicopathological Characteristics of Gastric Cancer?
    Lee H; Hwang IS; Choi IJ; Kang YN; Park KU; Lee JH
    Asian Pac J Cancer Prev; 2015; 16(11):4493-6. PubMed ID: 26107192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
    Balschun K; Haag J; Wenke AK; von Schönfels W; Schwarz NT; Röcken C
    J Mol Diagn; 2011 Jul; 13(4):436-45. PubMed ID: 21704278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.